10 results about "Sclerostin" patented technology

The present application provides methods of use, specifically methods of treatment of a disease, disorder, or condition (e.g, a low bone mass condition such as osteoporosis) in a human individual, comprising administration of novel bispecific antibodies that bind to both sclerostin and DKK-1 (e.g, anti-Sclerostin x anti-DKK-1 bispecific antibodies). The present application also provides methods of increasing bone mineral density in a human individual comprising administration of novel anti-Scl erostin x anti-DKK-1 bispecific antibodies. The present application further provides methods of reducing risk of bone fracture (e.g., osteoporotic fracture) in a human individual comprising administration of novel anti-Sclerostin x anti-DKK-1 bispecific antibodies.

The application belongs to the technical field of medical products and health products, and particularly relates to a compound targeting sclerostin and application thereof. A novel small-molecule compound is found and prepared, the small-molecule compound has good sclerostin binding capacity, sclerostin inhibition and the like, and can be used as a candidate drug for preventing or treating osteoporosis and bone fracture.

Aspects of the disclosure relate to compositions and methods for treating diseases or disorders associated with bone fracture and critical-sized bone defect. In some embodiments, the disclosure provides isolated nucleic acids and expression constructs (e.g., rAAVs, etc.) that encode one or both of the inhibitory nucleic acids targeting Schnurri 3 (SHN3) and the inhibitory nucleic acids targeting sclerostin (SOST).

The present application belongs to the field of biomedical and cosmetic technology, and particularly relates to the application of periostin in the preparation of preparations for promoting the activity of hair follicle cells or for preventing and treating alopecia. The present application first discovers that periostin has the activity of regulating hair follicle papilla cells, hair matrix cells and outer root sheath cells, can promote the proliferation of hair follicle papilla cells, hair matrix cells and outer root sheath cells, improve the hair induction ability of hair follicle papilla cells, and promote the hair follicle cycle transformation, hair growth and thickening, and can be applied to the preparation of preparations for treating alopecia.

The present application provides anti-Sclerostin constructs that bind to Sclerostin, nucleic acid molecules encoding an amino acid sequence of the anti-Sclerostin construct, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-Sclerostin construct, pharmaceutical compositions containing the anti-Sclerostin construct, and methods of using the anti-Sclerostin construct or compositions.

The present invention relates to an antibody that specifically binds to sclerostin of SEQ ID NO: 1, characterized in that the antibody comprises a heavy chain comprising the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8) at the C-terminal end of the heavy chain, wherein the antibody comprises a light chain amino acid sequence exposed in SEQ ID NO: 12 and a heavy chain amino acid sequence exposed in SEQ ID NO: 13 or SEQ ID NO: 14.

Provided is the use of a mulberry total polyphenol extract in the preparation of a product for promoting bone formation. The active ingredients of the mulberry total polyphenol extract include phenolic acids, polyphenol derivatives, flavones, isoflavones and tannins. The product for promoting bone formation can promote osteoblast proliferation, promote osteogenic calcification, inhibit sclerostin activity, and / or promote bone growth.

The present application relates to the technical field of biological medicine, and discloses a screening and verification method of a small-molecule inhibitor targeting a specific domain of sclerostin. The compound provided by the present application is obtained by structural modification, skeleton derivation design and molecular docking screening of a lead small-molecule compound tetrahydrofolic acid targeting the loop3 domain of sclerostin. The compound can specifically target and combine with the loop3 domain of sclerostin, can re-activate the Wnt signal inhibited by sclerostin, and restore the effect of Wnt signal in promoting bone formation. The sclerostin inhibitor containing the compound can inhibit various muscle-skeletal system diseases mediated by sclerostin activation, has wide application range and strong targeting property. Based on the characteristics that the compound targets and combines with the loop3 domain of sclerostin but not the loop2 domain, when the compound is used for preparing a drug for preventing and treating diseases mediated by sclerostin, the risk of cardiovascular diseases caused in the process of using the drug can be reduced.

The present invention relates to aptamer conjugates for targeted degradation of sclerostin, and more particularly, to aptamer conjugates for targeted degradation of sclerostin. In particular, the present invention relates to conjugates of aptamers directed to osteosclerosis proteins and ligands capable of targeting the protein degradation pathway, and uses of the conjugates for degrading osteosclerosis proteins.

Bispecific antibodies that target both human RANKL and sclerostin are provided. Also provided herein are polynucleotides encoding the bispecific antibodies, pharmaceutical compositions comprising the bispecific antibodies, and methods of producing the bispecific antibodies. Medical uses of the bispecific antibodies described herein are also disclosed.